February 27, 2019
Taiho Pharmaceutical said on February 26 that the US FDA has approved its anticancer agent Lonsurf (trifluridine + tipiracil) for an additional indication of gastric cancer. The drug has been reviewed on the agency’s priority pathway. The FDA granted approval...read more